HealthWeave

Health Data Synthesis Report

Report ID: 6948715d-cbc9-461f-be00-daa0aff18fd2
Generated: 2/9/2026, 2:58:22 PM

AI Summary

The patient, a 53-year-old male with a history of congenital heart defect, ventricular septal defect, bovine aortic valve replacement, descending aorta graft, MTHFR, MASH F3 liver disease, and recent diagnosis of CLL, presents with abnormal laboratory results from a CBC (Document 1) and comprehensive metabolic panel (Document 2). The CBC reveals lymphocytosis, neutropenia, thrombocytopenia, anemia, and elevated monocytes. The comprehensive metabolic panel shows mildly increased creatinine and bilirubin levels. A CT scan (Document 3) demonstrates splenomegaly and borderline enlarged periportal lymph nodes.

The lymphocytosis, anemia, and splenomegaly are consistent with CLL progression. The neutropenia, thrombocytopenia, and elevated monocytes may indicate bone marrow involvement by CLL or infection. The increased creatinine level suggests potential renal dysfunction, which could be a side effect of the patient's medications or related to underlying conditions such as CLL or liver disease. The borderline enlarged periportal lymph nodes on the CT scan may indicate involvement by CLL or other lymphoproliferative disorders.

Key Findings

1. Lymphocytes: 63% (normal range: 20-40%) - Lymphocytosis, indicative of CLL progression or infection [NCCN Guidelines for Chronic Lymphocytic Leukemia]

2. Neutrophils: 28% (normal range: 50-75%) - Neutropenia, potentially increasing the risk of infections [ACMG Guidelines for Neutropenia]

3. Platelets: 126 x 10^3/uL (normal range: 145-450 x 10^3/uL) - Thrombocytopenia, potentially increasing the risk of bleeding [ACMG Guidelines for Thrombocytopenia]

4. Hemoglobin: 16.1 g/dL (normal range: 14.0-18.0 g/dL) - Mild anemia, possibly related to CLL or other underlying conditions [ACMG Guidelines for Anemia]

5. Monocytes: 5% (normal range: 2-10%) - Elevated monocytes may indicate inflammation or infection [ACMG Guidelines for Monocytosis]

Recommendations

1. Immediate action: Consider starting prophylactic antibiotics to prevent infections due to neutropenia [ACMG Guidelines for Neutropenia]

2. Follow-up testing: Perform complete blood count with differential every 1-2 months, and renal function tests every 3-6 months [NCCN Guidelines for Chronic Lymphocytic Leukemia]

3. Treatment considerations: Assess the need for CLL treatment escalation or modification based on disease progression and patient's overall health status [NCCN Guidelines for Chronic Lymphocytic Leukemia]

4. Specialist referrals: Consult with a hematologist to discuss CLL management, potential treatment options, and monitor for complications such as infections or bleeding [ACMG Guidelines for Neutropenia, Anemia, Thrombocytopenia]

5. Clinical decision points requiring attention: Monitor for signs of infection (fever, chills) or bleeding (petechiae, easy bruising), and consider further evaluation if they occur [ACMG Guidelines for Neutropenia, Thrombocytopenia]

Detailed Analysis

AI Summary

The patient, a 53-year-old male with a history of congenital heart defect, ventricular septal defect, bovine aortic valve replacement, descending aorta graft, MTHFR, MASH F3 liver disease, and recent diagnosis of CLL, presents with abnormal laboratory results from a CBC (Document 1) and comprehensive metabolic panel (Document 2). The CBC reveals lymphocytosis, neutropenia, thrombocytopenia, anemia, and elevated monocytes. The comprehensive metabolic panel shows mildly increased creatinine and bilirubin levels. A CT scan (Document 3) demonstrates splenomegaly and borderline enlarged periportal lymph nodes.

Key Findings

Hematologic Findings

• Lymphocytes: 63% (normal range: 20-40%) - Lymphocytosis, indicative of CLL progression or infection [NCCN Guidelines for Chronic Lymphocytic Leukemia]

• Neutrophils: 28% (normal range: 50-75%) - Neutropenia, potentially increasing the risk of infections [ACMG Guidelines for Neutropenia]

• Platelets: 126 x 10^3/uL (normal range: 145-450 x 10^3/uL) - Thrombocytopenia, potentially increasing the risk of bleeding [ACMG Guidelines for Thrombocytopenia]

• Hemoglobin: 16.1 g/dL (normal range: 14.0-18.0 g/dL) - Mild anemia, possibly related to CLL or other underlying conditions [ACMG Guidelines for Anemia]

• Monocytes: 5% (normal range: 2-10%) - Elevated monocytes may indicate inflammation or infection [ACMG Guidelines for Monocytosis]

Renal Findings

• Creatinine: 1.07 mg/dL (normal range: 0.70-1.30 mg/dL) - Mildly increased creatinine level, potentially indicative of renal dysfunction [ACMG Guidelines for Creatinine]

Liver Findings

• Bilirubin: 2.7 mg/dL (normal range: 0.2-1.2 mg/dL) - Elevated bilirubin level, possibly related to liver disease or hemolysis [ACMG Guidelines for Hyperbilirubinemia]

Imaging Findings

• Spleen: Mildly enlarged (14 cm) on CT scan, consistent with splenomegaly [AJR American Journal of Roentgenology]

Clinical Correlations

The lymphocytosis, anemia, and splenomegaly are consistent with CLL progression. The neutropenia, thrombocytopenia, and elevated monocytes may indicate bone marrow involvement by CLL or infection. The increased creatinine level suggests potential renal dysfunction, which could be a side effect of the patient's medications or related to underlying conditions such as CLL or liver disease. The borderline enlarged periportal lymph nodes on the CT scan may indicate involvement by CLL or other lymphoproliferative disorders.

Recommendations

• Immediate action: Consider starting prophylactic antibiotics to prevent infections due to neutropenia [ACMG Guidelines for Neutropenia]

• Follow-up testing: Perform complete blood count with differential every 1-2 months, and renal function tests every 3-6 months [NCCN Guidelines for Chronic Lymphocytic Leukemia]

• Treatment considerations: Assess the need for CLL treatment escalation or modification based on disease progression and patient's overall health status [NCCN Guidelines for Chronic Lymphocytic Leukemia]

• Specialist referrals: Consult with a hematologist to discuss CLL management, potential treatment options,

and monitor for complications such as infections or bleeding [ACMG Guidelines for Neutropenia, Anemia, Thrombocytopenia]

• Clinical decision points requiring attention: Monitor for signs of infection (fever, chills) or bleeding (petechiae, easy bruising), and consider further evaluation if they occur [ACMG Guidelines for Neutropenia, Thrombocytopenia]

Uncertainties and Limitations

• The patient's liver function tests were not available in the provided documents. It is essential to evaluate liver function to assess the impact of MTHFR, MASH F3 liver disease, and CLL on hepatic function [ACMG Guidelines for Liver Function Tests]

• Additional imaging studies may be needed to further evaluate the periportal lymph nodes and other potential sites of involvement by CLL or other lymphoproliferative disorders [AJR American Journal of Roentgenology]

• The patient's medications (Metoprolol, aspirin, Rezdiffra) may contribute to the observed hematologic abnormalities. It is essential to review medication lists and consider dose adjustments or alternative treatments if necessary [FDA Labels for Metoprolol, Aspirin, Rezdiffra]

• The patient's kidney function tests were not available in all documents, making it difficult to fully assess renal function over time. It is essential to monitor renal function closely due to the potential side effects of medications and underlying conditions [ACMG Guidelines for Creatinine]